Tammy McClellan, PharmD, discusses the use of amivantamab plus chemotherapy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Tammy McClellan, PharmD
Advertisement
Articles by Tammy McClellan, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
